![学納金サイト [在学生・保護者専用]](/assets/images/BlkFeatured_item_tuition.jpg)
Faculty of Medicine教員紹介：櫻井 準
| 氏名 |
櫻井 準
サクライ ヒトシ SAKURAI, Hitoshi 
|
|---|---|
| 職位 | 講師 |
| 所属教室 | |
| 専攻・専門分野（大学院） |
医学専攻 精神神経科学分野（新課程） 内科系専攻 精神神経科学分野（旧課程） |
| 専門分野 | 臨床精神医学全般（特に気分障害）、精神科薬物療法 |
| 研究テーマ | なかなか良くならないうつ病におけるケタミン治療 |
| 略歴 | 出身大学 慶應義塾大学医学部 平成19年卒業 留学経験 アメリカ マサチューセッツ総合病院 |
| 所有する学位 | 博士（医学） |
| 指導医・専門医・認定医、その他の資格等 | 精神保健指定医 日本精神神経学会精神科専門医・指導医 日本臨床精神神経薬理学会専門医・指導医 |
| 論文・著書等を含む主要研究業績 |
詳細な業績は researchmap 研究者総覧 をご覧ください
2. Sakurai H (co-first), et al. Predictors of response to pharmacotherapy in children and adolescents with psychiatric disorders: a combined post-hoc analysis of four clinical trial data. Neuropsychopharmacol Rep 42(4): 516-520, 2022 3. Sakurai H, et al. Management of Unspecified Anxiety Disorder: Expert Consensus. Neuropsychopharmacol Rep (in press) 4. Sakurai H, et al. Novel Antidepressants in the Pipeline (Phase II and III): A Systematic Review of the US Clinical Trials Registry. Pharmacopsychiatry 55(4): 193-202, 2022 5. Sakurai H, et al. Use of Staging Models for Treatment-Resistant Depression Is Not Helpful in Predicting Non-response to Acute Intravenous Ketamine Treatment. J Clin Psychopharmacol 42(2):140-145, 2022 6. Sakurai H, et al. Residual symptoms after achieving remission with repetitive transcranial magnetic stimulation in depression. J Affect Disord 301:154-161, 2022 7. Sakurai H (co-first), et al. Validation of brief screening measures for depression and anxiety in young people with substance use disorders. J Affect Disord 282: 1021-1029, 2021 8. Sakurai H, et al. Long-term Outcome in Outpatients with Depression Treated with Acute and Maintenance Intravenous Ketamine: A Retrospective Chart Review. J Affect Disord 276: 660-666, 2020 9. Sakurai H, et al. Pharmacological Management of Bipolar Disorder: Japanese Expert Consensus. Bipolar Disord 22(8): 822-830, 2020 10. Sakurai H, et al. Pharmacological Treatment of Schizophrenia: Japanese Expert Consensus. Pharmacopsychiatry 54(2): 60-67, 2021 11. Sakurai H, et al. Pharmacological Management of Depression: Japanese Expert Consensus. J Affect Disord 266: 626-632, 2020 12. Sakurai H, et al. A Patient with Electroconvulsive Therapy-Resistant Major Depressive Disorder with a Full Response to Heated Yoga: A Case Report. J Psychiatr Pract 27(6): 486-491, 2021 13. Sakurai H, et al. A Patient with Treatment-resistant Depression Who Achieved Remission with Heated Yoga: A Case Report. Clinical Neuropsychopharmacology and Therapeutics 12: 12-17, 2021 14. Sakurai H et al. Improvement of Clinical Clerkship for Medical Students by Incorporating Ideas from Junior Residents: A Feasibility Study. Asian J Psychiatry 44: 110-111, 2019 15. Sakurai H (co-first), et al. Predicting Relapse with Residual Symptoms in Schizophrenia: Reappraisal of the PROACTIVE Trial. Schizophr Res 215: 173-180, 2020 16. Sakurai H, et al. Dose Increase of S-Adenosyl-Methionine and Escitalopram in a Randomized Clinical Trial for Major Depressive Disorder. J Affect Disord 262: 118-125, 2020 17. Sakurai H, et al. Longer-term open-label study of adjunctive riluzole in treatment-resistant depression. J Affect Disord 258: 102-108, 2019 18. Sakurai H, et al. Predicting relapse with individual residual symptoms in major depressive disorder: a reanalysis of the STAR*D data. Psychopharmacology (Berl) 234(16): 2453-2461, 2017 19. Sakurai H, et al. Increasing versus maintaining the dose of olanzapine or risperidone for schizophrenia patients who did not respond to modest dosage: a double-blind randomized controlled trial. J Clin Psychiatry 77(10): 1381-1390, 2016 20. Sakurai H, et al. Trajectories of individual symptoms in remitters versus non-remitters with depression. J Affect Disord 151(2): 506-513, 2013 21. Sakurai H, et al. Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. Schizophr Bull 39(3): 564-574, 2013 |
| 所属学会 |
日本精神神経学会 日本臨床精神神経薬理学会 日本神経精神薬理学会 日本うつ病学会 |